SEC Company Response from PULSE BIOSCIENCES, INC. (PLSE) (CIK 0001625101) (PLSE) — May 10, 2016
PULSE BIOSCIENCES, INC. (PLSE) (CIK 0001625101)
Date: May 10, 2016 · CIK: 0001625101 · Accession: 0001193125-16-585793
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-208694
Letter
Pulse Biosciences, Inc.
849 Mitten Road, Suite 104
Burlingame, CA 94010
May 10, 2016
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Attention: Tom Jones
Re: Pulse Biosciences, Inc.
Registration Statement on Form S-1
Registration No. 333-208694
Ladies and Gentlemen:
In connection with the above referenced Registration Statement, Pulse Biosciences, Inc. (the “Company”) hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of the effective date of said Registration Statement to 2:00 p.m. on May 13, 2016, or as soon thereafter as practicable.
In connection with the Registration Statement, the Company acknowledges that:
(1) should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
(2) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
(3) the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities law of the United States.
Pulse Biosciences, Inc
By:
/s/ Brian B. Dow
Brian B. Dow,
Chief Financial Officer
Show Raw Text
CORRESP 1 filename1.htm CORRESP Pulse Biosciences, Inc. 849 Mitten Road, Suite 104 Burlingame, CA 94010 May 10, 2016 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Tom Jones Re: Pulse Biosciences, Inc. Registration Statement on Form S-1 Registration No. 333-208694 Ladies and Gentlemen: In connection with the above referenced Registration Statement, Pulse Biosciences, Inc. (the “Company”) hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of the effective date of said Registration Statement to 2:00 p.m. on May 13, 2016, or as soon thereafter as practicable. In connection with the Registration Statement, the Company acknowledges that: (1) should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; (2) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and (3) the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities law of the United States. Pulse Biosciences, Inc By: /s/ Brian B. Dow Brian B. Dow, Chief Financial Officer